Abstract
Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clinical trials as a candidate drug for some oncological indications. Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies. This article reviews known roscovitine bioisosteres that have been prepared as CDK inhibitors using different core heterocycles. The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochemical activity - only six direct analogs containing different purine bioisosteres have been prepared and evaluated side by side with roscovitine. Only four types of bioisosteres have demonstrated improved biological properties, namely pyrazolo[ 1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.
Keywords: Cancer, cyclin-dependent kinase, inhibitor, roscovitine, bioisostere, oncogenes, purine, clinical trials, enantiomers, CDK active site
Current Pharmaceutical Design
Title:Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres
Volume: 18 Issue: 20
Author(s): Radek Jorda, Kamil Paruch and Vladimir Krystof
Affiliation:
Keywords: Cancer, cyclin-dependent kinase, inhibitor, roscovitine, bioisostere, oncogenes, purine, clinical trials, enantiomers, CDK active site
Abstract: Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clinical trials as a candidate drug for some oncological indications. Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies. This article reviews known roscovitine bioisosteres that have been prepared as CDK inhibitors using different core heterocycles. The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochemical activity - only six direct analogs containing different purine bioisosteres have been prepared and evaluated side by side with roscovitine. Only four types of bioisosteres have demonstrated improved biological properties, namely pyrazolo[ 1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.
Export Options
About this article
Cite this article as:
Jorda Radek, Paruch Kamil and Krystof Vladimir, Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres, Current Pharmaceutical Design 2012; 18 (20) . https://dx.doi.org/10.2174/138161212800672804
DOI https://dx.doi.org/10.2174/138161212800672804 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
Current Molecular Medicine NF-κB as a Therapeutic Target for Transcription Factor Decoy Strategy in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry The Autism Candidate Gene Neurobeachin Encodes a Scaffolding Protein Implicated in Membrane Trafficking and Signaling
Current Molecular Medicine Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design The Different Roles of The Channel-Kinases TRPM6 and TRPM7
Current Medicinal Chemistry HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
Current Cancer Drug Targets Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer
Current Cancer Drug Targets Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Whole Organism Based Techniques and Approaches in Early Stage Oncology Drug Discovery-Patents and Trends
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Differential Binding Preference of Methylpheophorbide a and Its Diboronated Derivatives to Albumin and Low Density Lipoproteins
Anti-Cancer Agents in Medicinal Chemistry Integrin-Mediated Drug Resistance
Current Signal Transduction Therapy Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Viral Elements Sense Tumorigenic Processes:Approaching Selective Cancer Therapy
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)]
Current Molecular Medicine Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design